New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BIIB;RHHBY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 27, 2015
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the companyís Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
07:51 EDTBIIBBiogen upgraded on valuation at Bernstein
Subscribe for More Information
07:50 EDTBIIBBiogen price target lowered to $330 from $422 at UBS
Subscribe for More Information
07:34 EDTBIIBBiogen enters collaboration with Parkinson's Institute and Clinical Center
Biogen and the Parkinsonís Institute and Clinical Center today announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinsonís disease and the creation of novel tools and programs that could accelerate research and the development of new PD treatments. The agreement will combine the unique clinical expertise and data of the Institute with Biogenís focus on neurodegenerative disease and approach to clinical development. Under the terms of the agreement, Biogen will fund research activities by the Institute and provide strategic insight into research design, data analysis, and program support.
07:04 EDTBIIBBiogen downgraded on 'diminished' growth prospects at Baird
Baird analyst Brian Skorney downgraded Biogen to Neutral from Outperform and cut his price target for shares to $316. The stock closed Friday down $85.02 to $300.03. Skorney sees "diminished" growth prospects for the company and wants greater confidence in management's guidance before recommending the stock. He admits, however, that his downgrade "may be too little, too late." JPMorgan analyst Cory Kasimov this morning called Biogen's risk/reward compelling following Friday's selloff.
06:39 EDTBIIBBiogen shares look oversold, says JPMorgan
Subscribe for More Information
06:05 EDTBIIBBiogen downgraded to Neutral from Outperform at Baird
Subscribe for More Information
July 24, 2015
16:22 EDTBIIBOn The Fly: Top stock stories for Friday
Subscribe for More Information
12:54 EDTBIIBOn The Fly: Top stock stories at midday
Subscribe for More Information
11:50 EDTBIIBBiogen downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
11:21 EDTBIIBBiogen may retest low of the day, levels to watch
Subscribe for More Information
10:23 EDTBIIBBiogen price target lowered to $361 from $410 at Piper Jaffray
Subscribe for More Information
09:59 EDTBIIBBiogen breaks support intraday, levels to watch
Subscribe for More Information
09:36 EDTBIIBActive equity options trading on open
Subscribe for More Information
09:30 EDTBIIBBiogen CEO says will be 'aggressive,' will 'not be shy' about right M&A
Subscribe for More Information
09:28 EDTBIIBBiogen drops sharply after earnings
Subscribe for More Information
09:14 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Amazon (AMZN), up 20.7%... Pandora (P), up 10.3%... Juniper (JNPR), up 9.1%... Visa (V), up 6.7%... Starbucks (SBUX), up 5%... Skyworks (SWKS), up 2.6%... American Airlines (AAL), up 2.1%. ALSO HIGHER: SolarCity (SCTY), up 2.5% after being upgraded to Outperform from Neutral at Baird. DOWN AFTER EARNINGS: Tripadvisor (TRIP), down 8.5%... Biogen (BIIB), down 14.1%.
08:54 EDTBIIBBiogen sees limited U.S. patient growth for Tecfidera in rest of FY15
Subscribe for More Information
08:48 EDTBIIBTecfidera U.S. switch rates below expectations in Q2, EVP says
In the U.S. in Q2, Tecfidera total market growth and switch rates remained lower than Biogen's original expectations and appeared to have returned to historical averages typically seen in the market before launch, said EVP of Global Commercial Operations Tony Kingsley. "We believe the safety event reported in late 2014 has created greater caution on the part of both physicians and patients about switching to orals. Our U.S. market research indicates a moderation in physician intent to prescribe, though in Q2 Tecfidera continued to gain patients in the U.S.," Kingsley said. Tecfidera patient growth for Europe "as a whole was robust," though total European Tecfidera revenue was dampened both by the change of price and softer demand in Germany, the executive added.
08:44 EDTBIIBBiogen CEO says expected reacceleration of Tecfidera not seen in Q2
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use